Newsletter Subscribe
Enter your email address below and subscribe to our newsletter
Research & Studies
Share your love
LENSAR Receives EU Certification for ALLY®
First EU ALLY Commercial Installation Expected in August 2024 ORLANDO, Fla.—LENSAR, Inc. (Nasdaq: LNSR), a global medical technology company specializing in advanced laser solutions for cataract treatment, announced that the ALLY Adaptive Cataract Treatment System has achieved certification under the…
What’s in Store for ESCRS 2024? Workshops, Labs, and More
The European Society of Cataract and Refractive Surgeons (ESCRS) is gearing up for its 42nd Annual Congress with a rich lineup of initiatives designed to enhance learning, foster collaboration, and celebrate advancements in ophthalmology. This year’s event will feature a…
Exclusive: Key Events at ESCRS 2024
The 42nd of the European Society of Cataract and Refractive Surgeons (ESCRS) is poised to offer a dynamic array of events and initiatives in 2024, featuring a mix of educational programs, commemorative milestones, and new insights into key areas of…
ViaLase Laser Granted CE Mark Approval for Glaucoma
ViaLase has received CE Mark approval in the European Union for its ViaLase laser, designed to treat adult patients with primary open-angle glaucoma. The ViaLase laser employs the precision of a femtosecond laser combined with micron-level image guidance to perform…
FDA Notifies Ocugen to Begin Expanded Access Program RP
The FDA has authorized Ocugen, Inc. to launch an expanded access program (EAP) for patients aged 18 and older with retinitis pigmentosa (RP), providing early access to its promising gene therapy candidate, OCU400. The treatment has shown encouraging results in…
Bausch + Lomb’s TENEO Laser Achieves Strong LASIK Outcomes
Bausch + Lomb recently published the results of a pivotal clinical trial for its TENEO™ Excimer Laser in the Journal of Refractive Surgery. This study, which played a crucial role in securing U.S. FDA approval for the device in January…
Ocular Therapeutix Enrolls First Patient in Phase 3 Wet AMD Study
Ocular Therapeutix announced that the first patients have been enrolled in its Phase 3 SOL-R clinical trial. This study aims to assess the repeat dosing of AXPAXLI™ (axitinib intravitreal implant, also known as OTX-TKI) for treating wet age-related macular degeneration…
Dr. Allen C. Ho Appointed Chairman of Alcon Research Institute
Alcon announced that Allen C. Ho, MD, will join the Alcon Research Institute’s (ARI) Executive Committee as chairman in October. The executive committee has overseen ARI’s mission to expand the frontiers of vision sciences globally since its founding in 1981,…
Researchers Discover Potential Therapeutic Target for Dry AMD
Researchers from the National Institutes of Health (NIH) have made a significant breakthrough in understanding the dysfunction associated with waste removal in the retina, offering new insights into dry age-related macular degeneration (AMD). A recent report from NIH and Johns…
GLP1RAs Linked to Higher DR Progression Risk vs. SGLT2is
A new study published online July 19 in Diabetes, Obesity and Metabolism has highlighted significant concerns regarding the treatment of diabetic retinopathy (DR) in patients with diabetes. The research indicates that treatment with glucagon-like peptide 1 receptor agonists (GLP1RAs) is…